Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

66.77 +0.24 (+0.36%)
Streaming Delayed Price Updated: 11:48 AM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
26 27 Next >
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Evotec Expands Neuroscience Collaboration with Bristol Myers
Bristol Myers Squibb & Co (NYSE: BMY) has expanded its neuroscience collaboration with Evotec SE (OTC: EVTCY) to include a new cell type. Related:... 
Via Benzinga
Markets Boosted
Good news helped stock prices. 
Via Talk Markets
Bristol Myers' TYK2 Inhibitor Disappoints In Mid-Stage Ulcerative Colitis Study
Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from the Phase 2 LATTICE-UC study evaluating deucravacitinib in moderate to severe ulcerative... 
Via Benzinga
Best Pharmaceutical Stocks To Buy In 2021
The global pharmaceutical market has experienced significant growth in recent years. As of end-2020, the total global pharmaceutical market was valued at about 1.27 trillion U.S. dollars. 
Via Talk Markets
Cannabis Movers & Shakers: TOCC, 1933 Industries, Iter Investments, Greenlane
Former Tilray Exec Steven Yoo Named Texas Original Compassionate Cultivation's New CFO Texas medical cannabis provider,&n... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
2 Ridiculously Cheap Growth Stocks to Buy
Though these companies have recorded solid financials of late, investors are overlooking them. 
Via The Motley Fool
Bristol Myers Squibb: Should You Buy the Dip?
Short-term volatility can be a patient, long-term investor's best friend. 
Via The Motley Fool
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Merck Puts Up $11.5 Billion In Acceleron Deal As It Expands Its Cancer Dominance
Merck will buy a company focused, partly, on blood cancer treatment. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Merck Seals Acceleron Pharma Deal For $180/Share: Highlights
Putting all the speculations at bay, Merck & Co Inc (NYSE: MRK) has agreed to acquire Acceleron Pharma Inc (NASDAQ: XLRN) for $180 per share in cash... 
Via Benzinga
A Bit Of A Recovery
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
These 3 Top Healthcare Stocks Are Screaming Buys Right Now
If the market crashes these companies could be insulated. 
Via The Motley Fool
AstraZeneca's Saphnelo For Lupus Treatment Approved In Japan
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved AstraZeneca plc’s (NASDAQ: AZN) Saphnelo (anifrolumab) for systemic lupus... 
Via Benzinga
Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ
The Wall Street Journal reported that Merck & Co Inc (NYSE: MRK) is in advanced talks to acquire Acceleron Pharma Inc (NASDAQ: XLRN), citing... 
Via Benzinga
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
Bristol Myers' Two Opdivo Based Regimes Under FDA Review For Esophageal Cancer
The FDA has accepted for review Bristol Myers Squibb & Co Inc's (NYSE: BMY) supplemental marketing applications seeking approval for two Opdivo (nivolumab... 
Via Benzinga
Exposures Product Safety
Acceleron In Advanced $11B Buyout Talks: Bloomberg
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is... 
Via Benzinga
Bristol Myers: Worries Create Opportunity
Bristol Myers Squibb Company sells at a low valuation due to worries over patent expirations. However, the company is working to replace the eventual revenue losses by developing its robust product... 
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
Is Bristol Myers Squibb Stock a Buy?
Maybe, but not if you're looking for major growth over the short term. 
Via The Motley Fool
89 Firms going Ex-Dividend next week, including Philip Morris, Cardinal Health and Nutrien
Several well-known large-cap stocks going ex-dividend next week 
Via Talk Markets
Why Acceleron Pharma Stock Jumped This Week
Buyout rumors are swirling around this mid-cap biotech company. 
Via The Motley Fool
3 Cheap Healthcare Stocks to Buy Right Now
The COVID-19 pandemic brought a renewed interest into the healthcare sector, and with the surging Delta variant raging across the country, that interest isn’t expected to dissipate anytime soon. 
Via Talk Markets
Exposures COVID-19
Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale
Key takeaways: • Less than two weeks after JW Therapeutics received regulatory approval to commercialize its core product in China, key early... 
Via Benzinga
4 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Investors Cheer Onconova's Rigosertib Combo Data In Lung Cancer Setting
Onconova Therapeutics Inc (NASDAQ: ONTX) has announced preliminary data from Phase 1/2a trial of rigosertib plus Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (... 
Via Benzinga
Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500 of sitravatinib combined... 
Via Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Exposures Product Safety
Visualizing the World’s Biggest Pharmaceutical Companies
Some of the world’s biggest pharmaceutical companies have played a central role in the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.